Next Article in Journal
Prognostic Relevance of Circulating 25OHD Fractions for Early Recovery and Survival in Patients with Hip Fracture
Next Article in Special Issue
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Previous Article in Journal
Brief Review: Ergospirometry in Patients with Obstructive Sleep Apnea Syndrome
Previous Article in Special Issue
Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine
Open AccessReview

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

1
Chris O’Brien Lifehouse, 119-143 Missenden Road Camperdown, Camperdown, NSW 2050, Australia
2
Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia
3
School of Medicine, Western Sydney University, Sydney, NSW 2560, Australia
4
Royal Prince Alfred Hospital, 50 Missenden Road Camperdown, Camperdown, NSW 2050, Australia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(8), 192; https://doi.org/10.3390/jcm7080192
Received: 20 July 2018 / Revised: 30 July 2018 / Accepted: 30 July 2018 / Published: 31 July 2018
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC. View Full-Text
Keywords: personalized therapy; non-small cell; lung cancer; targeted therapy; mutation; rearrangement personalized therapy; non-small cell; lung cancer; targeted therapy; mutation; rearrangement
MDPI and ACS Style

Bui, K.T.; Cooper, W.A.; Kao, S.; Boyer, M. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J. Clin. Med. 2018, 7, 192.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop